Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Sedatives and Hypnotics Drugs: Benzodiazepines

Sedatives and Hypnotics Drugs: Benzodiazepines

Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...

CNS Depressants: Barbiturates and Benzodiazepines

CNS Depressants: Barbiturates and Benzodiazepines

CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...

Anxiolytic Drugs: Benzodiazepines and Buspirone

Anxiolytic Drugs: Benzodiazepines and Buspirone

Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

Sedatives and Hypnotics: Overview

Sedatives and Hypnotics: Overview

Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...

Sedatives and Hypnotics Drugs: Barbiturates

Sedatives and Hypnotics Drugs: Barbiturates

Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pharmacogenetics in sexualized drug use: considerations for a precision addiction medicine approach.

The journal of sexual medicine·2026

Same author

Deltamethrin Placental Transfer and Seasonal Pyrethroid Exposure: A Mother-Newborn Dyad Pilot Study.

Therapeutic drug monitoring·2026

Same author

Unexpected Voriconazole Overexposure in a CYP2C19 Rapid Metabolizer Due to Inflammation-Induced Phenoconversion: A Short Communication.

Therapeutic drug monitoring·2026

Same author

Mapping the human chemical exposome for public health.

Nature medicine·2026

Same author

Impact of War-Related Bowel Resection on Pain Management: Is There Need for a Tailored Prescribing Approach? A Letter to the Editor.

Therapeutic drug monitoring·2026

Same author

Assessing Lead Exposure by Biological Matrices Analysis and Links to Breast Cancer: A Critical Review of Experimental and Epidemiological Findings.

European journal of breast health·2025

Search research articles

Related Experiment Video

Updated: Aug 11, 2025

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Designer Benzodiazepines: Effects, Toxicity, and Interactions.

Souleiman El Balkhi^1,2, Chadi Abbara³

¹Department of Pharmacology, Toxicology and Pharmacovigilance, Limoges University Hospital, Limoges.

Therapeutic Drug Monitoring

|February 7, 2023

Summary

Designer benzodiazepines (DBZDs) interact with GABA A receptors, causing effects similar to therapeutic benzodiazepines. Understanding their complex pharmacology is crucial for clinical management, especially with co-abused substances.

More Related Videos

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

Related Experiment Videos

Last Updated: Aug 11, 2025

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

Area of Science:

Pharmacology
Neuroscience
Toxicology

Background:

Designer benzodiazepines (DBZDs) are increasingly prevalent new psychoactive substances, demanding significant attention due to their popularity and availability.
While constituting a minor part of new psychoactive substances, DBZDs' rising use necessitates a comprehensive understanding of their effects and risks.

Approach:

A narrative review was conducted using a nonsystematic search of major scientific databases (PubMed, EMBASE, Google Scholar, PubMed Central) from June to July 2021.
The review synthesized information on DBZD effects, evaluation tools, toxicity, and drug interactions.

Key Points:

DBZDs act on GABA A receptors, producing effects like sedation, anxiolysis, and addiction, mirroring therapeutic benzodiazepines.
Pharmacodynamic properties are complex due to GABA A receptor subtypes; quantitative structure-activity relationships predict potency but not primary effects.
DBZDs are often used in polysubstance abuse, with significant reported pharmacodynamic interactions with CNS depressants like opioids, though pharmacokinetic interactions are less clear.

Conclusions:

Understanding DBZD mechanisms of action and pharmacological metrics is vital for effective clinical management.
Further research is needed to fully elucidate the complex interactions and clinical significance of DBZD use, particularly in polysubstance abuse scenarios.